Open AccessTherapeutic Aptamers: Evolving to Find their Clinical Niche
Author(s) -
Shahid M. Nimjee,
Bruce A. Sullenger
Publication year - 2020
Publication title -
current medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 174
eISSN - 1875-533X
pISSN - 0929-8673
DOI - 10.2174/0929867326666191001125101
Subject(s) - aptamer , systematic evolution of ligands by exponential enrichment , nucleic acid , oligonucleotide , computational biology , selex aptamer technique , drug discovery , chemistry , biology , bioinformatics , biochemistry , rna , microbiology and biotechnology , dna , gene
The discovery that short oligonucleotides, termed aptamers, can fold into three-dimensional structures that allow them to selectively bind and inhibit the activity of pathogenic proteins is now over 25 years old. The invention of the SELEX methodology heralded in an era in which such nucleic acid-based ligands could be generated against a wide variety of therapeutic targets.